2 weeks Ago
Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week. These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology. Here’s what you may have missed: Early Abnormalities Indicative of a Multiple Myeloma Diagnosis: Joshua Richter, MD Joshua Richter, MD , of The Tisch Cancer Institute, Blavatnik Family Chelsea Medical Center at Mount Sinai, discusses the importance of recognizing early signs of plasma cell disorders beyond just multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS).
He emphasizes that hallmark CRAB symptoms—elevated calcium, renal dysfunction, anemia, and bone lesions—should always prompt evaluation for plasma cell dyscrasias. Richter also highlights that disorders like light chain amyloidosis fall in a diagnostic gray zone and may present with low-level monoclonal spikes that are still clinically significant. He advises clinicians to consider the full clinical context, not just protein levels, when assessing potential plasma cell disorders.
Rationale for Evaluating MDC-CAR-BCMA001 in R/R Myeloma and AL Amyloidosis: Kiavasch Mohammad Nejad Farid, MD Kiavasch Mohammad Nejad Farid, MD , of Heidelberg University Hospital, discusses the compassionate use of a novel BCMA-directed CAR T-cell therapy, MDC-CAR-BCMA001, for patients with relapsed/refractory multiple myeloma and systemic light chain (AL) amyloidosis. He explains that although BCMA is a validated target in myeloma, CAR T-cell therapies are not currently approved for AL amyloidosis, prompting the need for alternative strategies. In a small cohort of six heavily pretreated patients, five achieved hematologic responses, including four complete responses and one very good partial response.
Additional benefits included minimal residual disease negativity and organ improvements, with a rapid median time to response of just 14 days. Optimal Timing of ESR1 Testing in HR+ Breast Cancer: Sara M. Tolaney, MD, MPH Sara M.
Tolaney, MD, MPH , of Dana-Farber Cancer Institute, discusses the potential of the SERENA-6 trial (NCT04964934) to change how ESR1 mutations are monitored in hormone receptor–positive breast cancer. Traditionally, ESR1 testing is performed at the time of disease progression, but emerging data suggest that earlier detection through serial circulating tumor DNA monitoring could allow for more timely treatment changes. The SERENA-6 trial demonstrated that switching to camizestrant upon early ESR1 mutation detection improved progression-free survival compared with continuing aromatase inhibitor therapy.
These findings support a new approach in clinical practice, where proactive ESR1 monitoring may guide earlier therapeutic intervention and improve patient outcomes. Use of Machine Learning to Predict Survival Outcomes After Allo-HSCT in Myelofibrosis: Adrián Mosquera Orgueira, MD, PhD Adrián Mosquera Orgueira, MD, PhD , of the Health Research Institute of Santiago de Compostela, discusses the use of a machine learning–based model to improve risk stratification in patients with myelofibrosis undergoing allogeneic stem cell transplant. The model, built using random survival forest techniques, outperformed traditional tools like the CIBMTR and Cox-derived scores in identifying high-risk patients.
By determining an optimal threshold—the top 25% of predicted risk—the model more than doubled the number of high-risk patients identified compared with conventional methods, better aligning with real-world clinical observations. This approach could enhance clinical decision making by more accurately flagging patients who may require intensified care or alternative treatment strategies. Value of Collaborating With Biomedical Engineers to Develop Preclinical Sarcoma Models: R.
Lor Randall, MD, FACS R. Lor Randall, MD, FACS , of University of California (UC) Davis Health, discusses the untapped potential of collaboration between oncologists and biomedical engineers to advance cancer research, particularly in sarcoma. He emphasizes that although oncologists typically work with molecular biologists and epidemiologists, engineers offer unique skills in designing physical and computational models that better simulate tumor biology.
At UC Davis, the strong engineering faculty presents opportunities to co-develop innovative preclinical platforms, such as 3D tissue constructs and organ-on-chip systems, to explore therapy response and resistance. Randall encourages academic oncologists to partner with engineering departments to build more precise, patient-relevant models that could drive progress in treatment development for rare and understudied cancers..
